C2I Alumna, RootPath, announces $11M Series A funding to accelerate clinical translation of their Pr

Congratulations to our alumna, RootPath, on raising $11 Million Series A funding to accelerate clinical translation of their personalized, highly-potent T cell therapy powered by their proprietary Synthetic Immunology Platform™! Rootpath will use the Series A funding to validate their tumor-reactive T cell receptor (TCR) discovery workflow, select a lead therapeutic candidate, and demonstrate its safety and efficacy in a preclinical setting and begin IND-enabling development.

To read more, view the official press release. Visit Rootpath's website by clicking here.

Book a virtual tour online by clicking here.